Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial
David Joseph, James W Denham, Allison Steigler, David S Lamb, Nigel A Spry, John Stanley, Tom Shannon, Gillian Duchesne, Chris Atkinson, John HL Matthews, Sandra Turner, Lizbeth Kenny, David Christie, Keen-Hun Tai, Nirdosh Kumar Gogna, Rachel Kearvell, Judy Murray, Martin A Ebert, Annette Haworth, Brett Delahunt Show all
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | ELSEVIER SCIENCE INC | Published : 2020
PURPOSE: To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer. METHODS AND MATERIALS: Participants with locally advanced prostate cancer in the TROG 03.04 RADAR trial were randomized to 6 or 18 months AS ± 18 months zoledronic acid (Z). The trial incorporated a RDE program by stratification at randomization and dosing options were 66, 70, or 74 Gy external beam radiation therapy (EBRT), or 46 Gy EBRT plus high-dose-rate brachytherapy boost (HDRB). The primary endpoint for this study was distant progression (DP). Secondary endpoints included local progression, bone ..View full abstract
Awarded by National Health and Medical Research Council of Australia
This work was supported by the National Health and Medical Research Council of Australia (Project Application ID 300705, 455521 and 1099149); The Goodfellow Foundation, Auckland (New Zealand); Cancer Standards Institute of New Zealand; Novartis Pharmaceuticals Australia; and AbbVie Pharmaceuticals Australia.